Patent 9365639 was granted and assigned to Visterra Inc. on June, 2016 by the United States Patent and Trademark Office.
Antibody molecules that specifically bind to dengue virus are disclosed. In certain embodiments, the antibody molecule bind to dengue virus serotypes DV-1, DV-2, DV-3, and DV-4. The antibody molecules can be used to treat, prevent, and/or diagnose dengue virus.